A Phase Ib Dose-Escalation Study to Assess the Safety and Tolerability of DV-601 in Subjects With Chronic Hepatitis B on Concurrent Treatment With a Nucleoside Analogue.
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2017
At a glance
- Drugs DV 601 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Dynavax Technologies
- 17 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Feb 2011 Additional immunogenicity and tolerability data have been reported in a Dynavax media release.
- 23 Dec 2010 Immunogenicity and tolerability data has been reported in a Dynavax media release.